Roquefort Therapeutics (LON:ROQ) Trading Down 9.4% – Should You Sell?

Roquefort Therapeutics plc (LON:ROQ) fell 9.4% on Friday . The stock traded as low as GBX 1.41 ($0.02) and last traded at GBX 1.41 ($0.02). 250,000 shares changed hands during trading, a decline of 88% from the average session volume of 2,026,446 shares. The stock had previously closed at GBX 1.55 ($0.02).

Roquefort Therapeutics Price Performance

The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The firm has a market cap of £1.92 million, a PE ratio of -1.25 and a beta of 0.05. The stock has a 50 day simple moving average of GBX 1.57 and a 200-day simple moving average of GBX 2.11.

Roquefort Therapeutics (LON:ROQ) last announced its earnings results on Wednesday, April 30th. The company reported GBX (0.75) (($0.01)) earnings per share (EPS) for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 29.57%.

Insider Buying and Selling at Roquefort Therapeutics

In other Roquefort Therapeutics news, insider Simon Sinclair acquired 72,507 shares of the company’s stock in a transaction dated Friday, June 27th. The stock was bought at an average price of GBX 1 ($0.01) per share, with a total value of £725.07 ($973.64). Also, insider Stephen Paul West purchased 2,400,000 shares of the firm’s stock in a transaction dated Friday, July 4th. The stock was acquired at an average cost of GBX 2 ($0.03) per share, with a total value of £48,000 ($64,455.49). 60.40% of the stock is currently owned by insiders.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.